Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry.
Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, Kheir WJ, Kok G, Vujosevic S, O'Toole L, Mangelschots E, Jaross N, Ceklic L, Daien V, Viola F, Squirrell D, Lavid FJ, Creuzot-Garcher C, Barthelmes D, Gillies M; Fight Retinal Blindness! Study Group. Mehta H, et al. Among authors: o toole l. Ophthalmol Retina. 2024 Apr 16:S2468-6530(24)00182-9. doi: 10.1016/j.oret.2024.04.008. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38615818 Free article.
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group; Li J. Haller JA, et al. Ophthalmology. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20. Ophthalmology. 2011. PMID: 21764136 Clinical Trial.
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry.
Hunt AR, Nguyen V, Creuzot-Garcher CP, Alforja S, Gabrielle PH, Zarranz-Ventura J, Guillemin M, Fraser-Bell S, Casaroli Marano RP, Arnold J, McAllister IL, O'Toole L, Gillies MC, Barthelmes D, Mehta H. Hunt AR, et al. Br J Ophthalmol. 2022 Aug;106(8):1178-1184. doi: 10.1136/bjophthalmol-2020-318491. Epub 2021 Mar 12. Br J Ophthalmol. 2022. PMID: 33712484
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry.
Hunt AR, Nguyen V, Arnold JJ, McAllister IL, Mehta H, Invernizzi A, Ponsioen T, Gabrielle PH, O'Toole L, Kusenda P, Alforja S, Barthelmes D, Gillies MC. Hunt AR, et al. Br J Ophthalmol. 2023 Jun;107(6):842-848. doi: 10.1136/bjophthalmol-2021-320482. Epub 2022 Jan 25. Br J Ophthalmol. 2023. PMID: 35078771 Free PMC article.
Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry.
Gabrielle PH, Maitrias S, Nguyen V, Arnold JJ, Squirrell D, Arnould L, Sanchez-Monroy J, Viola F, O'Toole L, Barthelmes D, Creuzot-Garcher C, Gillies M; Fight Retinal Blindness! Study Group. Gabrielle PH, et al. Acta Ophthalmol. 2022 Dec;100(8):e1569-e1578. doi: 10.1111/aos.15137. Epub 2022 Mar 23. Acta Ophthalmol. 2022. PMID: 35322568 Free PMC article.
154 results